PD-1 inhibitor

REDWOOD CITY, Calif., December 8, 2025 — Coherus Oncology today announced compelling six-year overall survival (OS) follow-up data from...

SHANGHAI, China, Nov. 25, 2025 — Junshi Biosciences announced that its Phase 3 clinical study evaluating JS001sc, a subcutaneous...